The effects of galantamine on psychopathology in chronic stable schizophrenia (Q33724801)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article

Language	Label	Description	Also known as
English	The effects of galantamine on psychopathology in chronic stable schizophrenia	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

The effects of galantamine on psychopathology in chronic stable schizophrenia (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

1 reference

based on heuristic

inferred from title

Robert R. Conley

1

object named as

Robert R Conley

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

author name string

Douglas L Boggs

2

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Deanna L Kelly

3

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Robert P McMahon

4

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Dwight Dickinson

5

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Stephanie Feldman

6

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

M Patricia Ball

7

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Robert W Buchanan

8

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 March 2009

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Clinical Neuropharmacology

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

32

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

69-74

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Treatment of tardive dyskinesia with galantamine: a randomized controlled crossover trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

21 June 2018

Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

21 June 2018

Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

21 June 2018

Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

21 June 2018

The NIMH-MATRICS consensus statement on negative symptoms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

21 June 2018

The structure of negative symptoms within schizophrenia: implications for assessment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

21 June 2018

Effects of nicotine nasal spray on cognitive function in schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

21 June 2018

A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

21 June 2018

Disorganization of semantic memory underlies alogia in schizophrenia: an analysis of verbal fluency performance in Japanese subjects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

21 June 2018

Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

21 June 2018

Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

21 June 2018

Nicotine decreases bradykinesia-rigidity in haloperidol-treated patients with schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

21 June 2018

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

21 June 2018

Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

21 June 2018

Nicotinic receptor desensitization and sensory gating deficits in schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

21 June 2018

Evaluation of treatment-resistant schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

21 June 2018

Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

21 June 2018

Negative symptoms in schizophrenia. Definition and reliability

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

21 June 2018

A rating scale for extrapyramidal side effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

21 June 2018

Galantamine for the treatment of cognitive impairments in people with schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

30 October 2018

The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

30 October 2018

A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

30 October 2018

Galantamine improves cognition in schizophrenic patients stabilized on risperidone.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

30 October 2018

Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

30 October 2018

Galantamine may improve attention and speech in schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

30 October 2018

Effects of nicotine on hippocampal and cingulate activity during smooth pursuit eye movement in schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

30 October 2018

Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

30 October 2018

Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind fMRI study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

30 October 2018

Adjuvant therapeutic effects of galantamine on apathy in a schizophrenia patient.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

30 October 2018

Assessment of capacity to give consent to research participation: state-of-the-art and beyond.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

30 October 2018

The Allosteric Potentiation of Nicotinic Acetylcholine Receptors by Galantamine Is Transduced into Cellular Responses in Neurons: Ca2+Signals and Neurotransmitter Release

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

30 October 2018

Differential effects of cigarette smoking on performance of a smooth pursuit and a saccadic eye movement task in schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

30 October 2018

Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

30 October 2018

Nicotine and behavioral markers of risk for schizophrenia: a double-blind, placebo-controlled, cross-over study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

30 October 2018

Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

30 October 2018

Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

30 October 2018

Galantamine for treatment-resistant schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

30 October 2018

Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4049075

30 October 2018

Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia I: sensitivity, reliability, and validity

1 reference

https://pubmed.ncbi.nlm.nih.gov/18978489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human post-mortem striatal alpha4beta2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/18978489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Schizophrenia and smoking: evidence for a common neurobiological basis?

1 reference

https://pubmed.ncbi.nlm.nih.gov/18978489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute feasibility and safety of a smoking reduction strategy for smokers with schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18978489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Normalization of auditory physiology by cigarette smoking in schizophrenic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/18978489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Galantamine added to antipsychotic treatment in chronic schizophrenia: cognitive improvement?

1 reference

https://pubmed.ncbi.nlm.nih.gov/18978489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Varenicline-induced manic episode in a patient with bipolar disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/18978489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Exacerbation of schizophrenia by varenicline

1 reference

https://pubmed.ncbi.nlm.nih.gov/18978489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates

1 reference

https://pubmed.ncbi.nlm.nih.gov/18978489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1097/WNF.0B013E31816F2795

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33724801&oldid=1978978165"